Article

PRL offers good results for high myopia

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia.

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia, according to Esther Arranz-Marquez and co-workers from Vissum Corporación Oftalmológica de Madrid, Spain.

In a prospective study, the PRL was implanted in 78 myopic eyes in which the refractive error ranged between -4.0 and -31.0 D and laser refractive surgery was contraindicated. Uncorrected and best corrected visual acuity (UCVA & BCVA), manifest and cycloplegic refractions and intraocular pressure (IOP) were assessed over a three-year follow-up period.

The results revealed a significant change in spherical equivalent from a preoperative mean value of -14.7±5.4 D to 0±0.8 D three years postoperatively (p<0.01). UCVA and BCVA also improved significantly (p<0.01). Although a significant increase in IOP was found at each postoperative visit (p<0.01), there was no significant difference in IOP between one and three years postoperatively. Four eyes were operated on again due to mild lens decentration.

It was concluded that implantation of a PRL can offer good and predictable results for the correction of high myopia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.